Supplementary Figures 1 - 7, Table 1 from A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells

PDF file - 1137K, Supplementary Figure 1: Tropomyosin siRNA knockdown is isoform specific and does not result in any compensation. Supplementary Figure 2: TR100 nullifies the impact of Tm5NM1 on actin filament depolymerization kinetics. Supplementary Figure 3: Anti-Tropomyosin compound impact on the actin cytoskeleton assessed by the microfilament disruption assay. Supplementary Figure 4: TR100 targets the actin cytoskeleton and preferentially disrupts LMW-cytoskeletal tropomyosin containing filaments. Supplementary Figure 5: TR100 shows no overt impact on synaptic integrity of hippocampal neurons. Supplementary Figure 6: TR100 induces apoptosis in tumor cells via a mitochondrial pathway. Supplementary Figure 7: TR100 does not impact liver function in vivo.Supplementary Table 1: Summary of impact of TR100 on tumor cell viability.